Announcing our densitas densityai™ software will be deployed in up to 24 clinics throughout Germany as part of a procurement for a major breast cancer screening trial.
Our software will be used to provide breast density measurements at point of care to identify women for supplemental breast cancer screening as part of the DIMASOS 2 Trial.The announcement highlights not just the importance to this trial of the software’s unique ability to process prior ‘for presentation’ mammograms from a wide range of scanner vendors, but to any practical clinical deployment.
What is the objective of the trial?
The trial will aim to establish whether combined mammography and ultrasound exams can improve early breast cancer detection. It will also explore if this can be done feasibly and cost-effectively in standard screening workflow.
Who is leading the trial?
The trial will be led by Prof. Dr. Sylvia H. Heywang-Köbrunner, M.D., Head of Referenzzentrum Mammographie München, internationally recognized for her pioneering work in contrast-enhanced breast MRI and modern biopsy procedures.
She will be using densitas densityai™ breast density measures to establish a supplemental ultrasound screening protocol in the DIMASOS 2 trial.
When asked about the trial, Dr. Heywang-Köbrunner said:
“Women with dense breasts are subject to the masking effect of mammographic density and its association with breast cancer risk. The objective of the DIMASOS 2 trial is to test whether combined mammography/ultrasound exams can improve early cancer detection and if this can feasibly and cost effectively be done in routine screening workflow.
The unique ability of the Densitas® software to analyze prior ‘for presentation’ mammograms from a wide range of mammography scanner vendor models is pivotal to this trial and is important for any practical clinical deployment.”
What is our densitas densityai™ software used for?
Our densitas densityai™ software delivers fully automated, standardized, and reproducible breast density assessments from standard DICOM clinical use mammograms.
Results from densitas densityai™ are generated by two distinct algorithms that decouple the breast density assessment into quantitative and qualitative scales in alignment with the ACR BI-RADS 4th and 5th edition density classification system.
These results can be incorporated into breast cancer risk models to provide standardized and reproducible patient-specific risk estimates.
Mo Abdolell, CEO of Densitas, had this to say about the procurement:
“Being selected as the vendor of choice to provide automated breast density assessment for the DIMASOS 2 Trial attests to our modern AI-driven technology superseding dated breast density algorithms developed prior to the introduction of the ACR BI-RADS 5th ed. density scale in 2013.
Densitas densityai™ processes the same clinical use images that radiologists examine, setting it apart by enabling seamless PACS-centric integrations and retrospective auditing capabilities of routinely archived exams. This makes it an ideal fit for the DIMASOS 2 trial.
More broadly this also simplifies clinical deployments, and is more cost effective and deeply integrated into radiologist reporting workflows with key applications and platforms that include Nuance PowerScribe One and PowerScribe 360 Reporting, The Nuance AI Marketplace, Blackford Platform and Curated Marketplace, Ikonopedia structured breast reporting and tracking software, TeraRecon’s AI interoperability platform, EnvoyAI, and Three Palm Software’s WorkstationOne.”
Interested in learning more about how our suite of solutions for digital mammography is helping move the needle in breast cancer screening?
Schedule a demo with a member of our sales team to get a tailored walkthrough of our entire suite of solutions offered as part of the densitasai™ platform.